Long-term safety of steroid-sparing immunosuppression in uveitis.

Cohort studyCurrent opinion in ophthalmology· Aug 2026

Long-term safety of steroid-sparing immunosuppression in uveitis.

John Placide, Ogul E Uner, Eric B Suhler

Read paper

UveitisCohort studyTreatment

Adalimumab shows no new safety signals in long-term extension for uveitis.

Long-term safety of steroid-sparing immunosuppression in uveitis.

John Placide … Eric B Suhler

Current opinion in ophthalmology · Aug 2026

Background

OF REVIEW: Corticosteroid-sparing immunosuppression is standard for chronic noninfectious uveitis, yet its long-term safety remains a dominant clinical concern.

Purpose

Corticosteroid-sparing immunosuppression is standard for chronic noninfectious uveitis, yet its long-term safety remains a dominant clinical concern.

Methods

RECENT FINDINGS: The largest cohort data show no statistically significant excess in overall or cancer mortality for antimetabolites, calcineurin inhibitors, or antitumor necrosis factor agents, whereas alkylating agents remain the principal malignancy concern.

7-year

Results

7-year

adalimumab showed no new safety signals in this long-term extension

“

Conclusion · 1 of 2

Steroid-sparing agents appear to have excellent long-term safety when the agent is matched to disease severity and patients are screened and monitored proactively.

Conclusion · 2 of 2

The safest agent is the one whose specific toxicity is anticipated and managed.

Long-term safety of steroid-sparing immunosuppression in uveitis.

Long-term safety of steroid-sparing immunosuppression in uveitis.

Related papers